Abbreviations

NIHSS
Section 510(k) of the Food Drug and Cosmetic Act requires device manufacturers, who must register, to notify the Food and Drug Administration (FDA) of their intent to market a medical device at least 90 days in advance. This is known as Premarket Notification-also called PMN or 510(k). This allows FDA to determine whether the device is equivalent to a device already placed into one of the three classification categories (more details at http:// www.fda.gov/medicaldevices/ productsandmedicalprocedures/ deviceapprovalsandclearances/ 510kclearances/default.htm).
The following are based on true stories (either from personal experience or conversations with colleagues at meetings).
Scenario 1
A 65-year-old otherwise healthy female patient presents with large left middle cerebral artery (MCA) stroke 80 min from onset and a National Institutes of Health Stroke Scale (NIHSS) of 21. Imaging shows a small core and occlusion in the M1 segment of the left middle cerebral artery. Stroke neurologist (to patient's son who is well educated, works as an accountant): Your mother is having a severe stroke due to blockage in one of the large vessels in her brain. This requires urgent intervention to give her the best chance of recovery. We are going to be starting her on a clot busting drug called tPA. However, we are also part of a randomized trial, to test a new therapy.
Patient's son: What is the new therapy? Stroke neurologist: Your mother would be taken to the cath lab where a small tube would be advanced to the vessels of the brain under X-ray guidance similar to what is done for a heart attack. Once it is in position, we would try and suck the clot out to reestablish flow to the brain. This procedure, however, is not a wellestablished procedure and does carry a risk. If you choose to participate in the trial, there is a 66 % chance that your mother will go to the cath lab. Of course, there is a one-third chance that she won't in which case, she would receive the intravenous clot busting drug and be shifted to the stroke unit. Patient gets randomized to intra-arterial (IA) therapy. The time from start of IV to groin puncture was 145 min. Questions 1. Does the overall circumstance influence the efficiency of care? 2. Does this lack of efficiency selectively affect one arm?
Scenario 4
A 58-year-old otherwise healthy man presents with aphasia, right-sided weakness, and a NIHSS of 12, 90 min from onset. He is brought over by ambulance.
There is no family with him. Imaging shows ASPECTS of 8, left M1 occlusion, and sizeable penumbra. Patient is started on IV tPA. The team wants to randomize the patient. It is now 0825 hours. However, there is no one to give consent. Paramedics say that family is on the way.
Stroke neurologist (to paramedic): Why didn't you get the family member along? Paramedic: We are not allowed to. The patient gets randomized to the IA arm and is taken to angio, and recanalization is achieved at 1145 hours. Questions 1. Is there a way to simplify the consent process for a very complex, urgent situation wherein the family is emotionally charged, suffering from information overload and likely to be in "analysis paralysis"?
Responses
Here are some of the responses that I got.
Dr. Worrier: IMS3 [1] and MR RESCUE [2] were futile. What will happen now? Already carotid stenting and intracranial stenting trials were negative. There will be no support to do IA therapy for acute stroke. How will I find a job at the end of the fellowship? A recent article in JNIS is calling for stopping neurointervention fellowships [3] . We should do something to make sure that IA therapy is protected. Dr. Warrior: Who said it was going to be easy? This is how real life is. We have to work together to work on solutions, achieve consensus, create systems that protect in the interests of the individual patient, allow freedom of decision making, promote innovation but still allow for practice of evidence-based medicine. Dr. Trialz Arking: We should stop all IA therapy outside of trials. There will be no way to patient to get to the angio suite unless they are part of the trial. In fact, the whole 510K process is flawed. We should get rid of that process altogether. Of note, none of the people gave any real, practical answers. There has been a lot of talk in recent meetings regarding the futility of IMS3. I have heard several people talk about (1) lack of sophisticated imaging in the trial and (2) lack of modern recanalization devices [4] . I wonder whether the questions raised above are more important for the success of future trials.
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